Phibro Animal Health Corporation Class A (PAHC) is a publicly traded Healthcare sector company. As of May 21, 2026, PAHC trades at $33.75 with a market cap of $1.39B and a P/E ratio of 14.56. PAHC moved -0.34% today. Year to date, PAHC is -11.88%; over the trailing twelve months it is +40.35%. Its 52-week range spans $16.16 to $60.08. Analyst consensus is neutral with an average price target of $44.00. Rallies surfaces PAHC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phibro Animal Health Q2 EPS 26.1% Above Estimates on $373.9M Revenue Beat: Phibro Animal Health reported Q2 adjusted EPS of $0.87, 26.1% above estimates, on revenues of $373.9 million, 4.7% higher than forecast. The company’s estimated long-term earnings growth rate of 21.5% outpaces the industry’s 12.5%, reflecting consistent quarter-over-quarter surprise averaging 20.1%.
| Metric | Value |
|---|---|
| Price | $33.75 |
| Market Cap | $1.39B |
| P/E Ratio | 14.56 |
| EPS | $2.34 |
| Dividend Yield | 0.12% |
| 52-Week High | $60.08 |
| 52-Week Low | $16.16 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.50B |
| Net Income | $95.23M |
| Gross Margin | 32.54% |
1 analysts cover PAHC: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.00.